PMID- 18217197
OWN - NLM
STAT- MEDLINE
DCOM- 20080520
LR  - 20220331
IS  - 1439-7595 (Print)
IS  - 1439-7595 (Linking)
VI  - 18
IP  - 1
DP  - 2008
TI  - Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients 
      with steroid-resistant polymyositis and dermatomyositis.
PG  - 34-44
LID - 10.1007/s10165-007-0013-0 [doi]
AB  - Intravenous immunoglobulin (IVIG) therapy was administered to 15 patients who 
      were refractory to traditional steroid therapy [eight with polymyosis (PM), seven 
      with dermamyosis (DM)] to evaluate its efficacy. Serum creatine kinase (CK) 
      significantly decreased from week 1, and manual muscle test scores (MMT) and 
      activities of daily living (ADL) significantly increased from week 2. Efficacy 
      rates were 93.3% (14/15 patients) as assessed using the MMT score, 80.0% (12/15 
      patients) using the ADL score, and 100% (15/15 patients) using the serum CK 
      level. When changes in the serum CK level over two four-week periods, one before 
      IVIG therapy (from week -4 to week 0) and one after IVIG therapy (from week 0 to 
      week 4), were transformed to natural logarithms, the four-week change after IVIG 
      therapy was significantly greater than that before IVIG therapy. The estimated 
      duration of the serum CK level remaining normal in 50% of the patients after IVIG 
      therapy was 334.5 days. Adverse reactions were observed in seven of 16 patients 
      (43.8%) during the study period, but none of the adverse reactions were 
      considered to be serious or required emergency treatment. In conclusion, the 
      present study indicates that IVIG therapy is effective for steroid-resistant 
      PM/DM.
FAU - Saito, Eizo
AU  - Saito E
AD  - Department of Rheumatology, Toho University Ohashi Medical Center, Tokyo, Japan. 
      saito@oha.toho-u.ac.jp
FAU - Koike, Takao
AU  - Koike T
FAU - Hashimoto, Hiroshi
AU  - Hashimoto H
FAU - Miyasaka, Nobuyuki
AU  - Miyasaka N
FAU - Ikeda, Yasuo
AU  - Ikeda Y
FAU - Hara, Masako
AU  - Hara M
FAU - Yamada, Hidehiro
AU  - Yamada H
FAU - Yoshida, Tadashi
AU  - Yoshida T
FAU - Harigai, Masayoshi
AU  - Harigai M
FAU - Ichikawa, Yoichi
AU  - Ichikawa Y
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080125
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 0 (Steroids)
SB  - IM
EIN - Mod Rheumatol. 2008;18(2):212
MH  - Adult
MH  - Dermatomyositis/*therapy
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Paraneoplastic Syndromes/*therapy
MH  - Steroids/therapeutic use
MH  - Treatment Outcome
EDAT- 2008/01/25 09:00
MHDA- 2008/05/21 09:00
CRDT- 2008/01/25 09:00
PHST- 2007/07/04 00:00 [received]
PHST- 2007/09/26 00:00 [accepted]
PHST- 2008/01/25 09:00 [pubmed]
PHST- 2008/05/21 09:00 [medline]
PHST- 2008/01/25 09:00 [entrez]
AID - 10.1007/s10165-007-0013-0 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2008;18(1):34-44. doi: 10.1007/s10165-007-0013-0. Epub 2008 Jan 
      25.